Informações:
Falhas:
ID
23463
Descrição
CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00526643
Link
https://clinicaltrials.gov/show/NCT00526643
Palavras-chave
Versões (1)
- 05/07/2017 05/07/2017 -
Transferido a
5 de julho de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Non-Small Cell Lung Cancer NCT00526643
Eligibility Non-Small Cell Lung Cancer NCT00526643
- StudyEvent: Eligibility
Similar models
Eligibility Non-Small Cell Lung Cancer NCT00526643
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
ID.1
Item
histologically or cytologically confirmed diagnosis of advanced non small cell lung cancer, not amenable to surgical or curative radiation therapy (stage iiib or iv);
boolean
C0007131 (UMLS CUI [1,1])
C1827320 (UMLS CUI [1,2])
C1828386 (UMLS CUI [1,3])
C1827320 (UMLS CUI [1,2])
C1828386 (UMLS CUI [1,3])
ID.2
Item
no prior or concomitant chemotherapy (adjuvant/neoadjuvant chemotherapy permitted if concluded at least one year prior to enrollment);
boolean
C0087111 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C0392920 (UMLS CUI [1,2])
ID.3
Item
ecog performance status 2;
boolean
C1520224 (UMLS CUI [1])
ID.4
Item
age: > or = 18 and < 70 years;
boolean
C0001779 (UMLS CUI [1])
ID.5
Item
life expectancy at least 4 weeks;
boolean
ID.6
Item
normal bone marrow, hepatic and renal function defined as: neutrophils > or = 2000/mm3, plt > or = 100,000/mm3, hb > or = 10.0 g/dl, bilirubin > or = 1.5 times the upper normal limit (unl), ast and alt < or = 3 times the unl (5 times in the presence of liver metastases), creatinine within normal limits;
boolean
C0005953 (UMLS CUI [1,1])
C0232804 (UMLS CUI [1,2])
C0232741 (UMLS CUI [1,3])
C0232804 (UMLS CUI [1,2])
C0232741 (UMLS CUI [1,3])
ID.7
Item
signed informed consent.
boolean
C0021430 (UMLS CUI [1])
ID.8
Item
active systemic infections;
boolean
C3714514 (UMLS CUI [1])
ID.9
Item
severe concomitant illness (congestive heart failure, angina pectoris, myocardial infarction within previous 6 months, cardiac arrhythmias under treatment, severe arterial hypertension, severe or uncontrolled diabetes mellitus);
boolean
C0012634 (UMLS CUI [1])
ID.10
Item
inadequate hepatic or renal function;
boolean
C0086565 (UMLS CUI [1,1])
C0022658 (UMLS CUI [1,2])
C0022658 (UMLS CUI [1,2])
ID.11
Item
radiation therapy ongoing or concluded within two weeks prior to enrollment;
boolean
C1522449 (UMLS CUI [1])
ID.12
Item
symptomatic cerebral metastases;
boolean
C0555278 (UMLS CUI [1])
ID.13
Item
previous chemotherapy for advanced disease;
boolean
C0278940 (UMLS CUI [1])
ID.14
Item
any condition that would, in the investigator's opinion, limit the patients ability to provide informed consent or to comply with study procedures;
boolean
C0004936 (UMLS CUI [1])
ID.15
Item
pregnant or nursing females;
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
C0006147 (UMLS CUI [1,2])
ID.16
Item
any malignancy within the past 5 years (except for adequately treated carcinoma in situ of the cervix or non melanoma skin cancer)
boolean
C0006826 (UMLS CUI [1])